PF-07985045
- Generic Name
- PF-07985045
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Phase 1
Recruiting
- Conditions
- Carcinoma, Pancreatic DuctalColorectal NeoplasmsCarcinoma, Non-Small-Cell Lung
- Interventions
- Combination Product: GemcitabineCombination Product: CetuximabCombination Product: FluorouracilCombination Product: PembrolizumabCombination Product: PF-07284892Combination Product: Nab-paclitaxelCombination Product: OxaliplatinCombination Product: SasanlimabCombination Product: pemetrexedCombination Product: LeucovorinCombination Product: CisplatinCombination Product: BevacizumabCombination Product: PaclitaxelCombination Product: Carboplatin
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 190
- Registration Number
- NCT06704724
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸City of Hope (City of Hope National Medical Center, City Of Hope Medical Center), Duarte, California, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath